Valence 로고
인기
로그인
Loading data for TCRT — first visit, this takes a few seconds.

관심목록에 추가

Alaunos Therapeutics Inc.

NasdaqCM: TCRT · 실시간 가격 · USD
1.96
+0.03 (1.55%)
종가 기준: Aug 19, 2026, 3:03 PM

Alaunos Therapeutics Inc. (TCRT) Stock Price, Analysis & Data

1.55%
매수호가1.69
시가총액4.59M
매출 (ttm)3K
순이익 (ttm)-4.21M
베타-0.96
EPS (ttm)-1.75
P/E (ttm)n/a
선행 P/E-3.13
P/B (ttm)3.47
P/S (ttm)1530.41
Earnings DateAug 14, 2025
매도호가2.31
거래량15,994
평균 거래량 (20일)15,391
시가2.05
전일 종가1.93
일중 범위1.85 - 2.05
52주 범위1.67 - 4.59
애널리스트n/a
목표주가n/a
배당n/a
배당락일n/a

TCRT 소개

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based i...

[더 보기]
산업 Biotechnology
섹터 Healthcare
IPO 일자 Aug 24, 2005
직원 수 1
상장 거래소 NasdaqCM
티커 TCRT
웹사이트 https://www.alaunos.com
전체 기업 정보

재무 실적

2025년 Alaunos Therapeutics의 매출은 5K로, 전년 10K 대비 -50% 감소했습니다. 순이익은 -4.18M로, -10.75% 감소했습니다.

재무제표

어닝 서프라이즈

Alaunos Therapeutics가 Apr 1, 2024에 분기 실적을 발표했습니다:
  • 매출 $0 예상치 하회 $0, 및 -100.00% 전년 대비 감소.
  • EPS -17.09 예상치 하회 -12.59, 및 -184.83% 전년 대비 감소.

    • 다음 실적 발표

    Alaunos Therapeutics Inc.의 실적 발표 예정일은 Aug 14, 2025, 장 마감 후입니다.
    애널리스트 예상 매출은 ... 업그레이드
    news image

    2개월 전 · Stocktwits

    Alaunos Reports Positive Preclinical Obesity Drug Results Across Weight, Liver, Insulin Markers

    Preclinical findings for obesity drug candidate ALN1003 showed metabolic improvements, adding to interest in next-generation treatments beyond GLP-1 drugs.

    news image

    9개월 전 · Associated Press Finance

    Ziopharm: Q3 Earnings Snapshot

    HOUSTON (AP) — Alaunos Therapeutics, Inc. TCRT) on Friday reported a loss of $1.2 million in its third quarter. The Houston-based company said it had a loss of 55 cents per share.

    news image

    1년 전 · Associated Press Finance

    Ziopharm: Q2 Earnings Snapshot

    HOUSTON (AP) — Alaunos Therapeutics, Inc. TCRT) on Thursday reported a loss of $1.1 million in its second quarter. On a per-share basis, the Houston-based company said it had a loss of 63 cents.